ZOMDF (Zomedica) 3-Year EPS without NRI Growth Rate: -10.60% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zomedica 3-Year EPS without NRI Growth Rate?

Zomedica ZOMDF +2.28% 3-Year EPS without NRI Growth Rate is -10.60% as of Jun. 2026. The stock has 2 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Zomedica ranks worse than 73.72% on this metric.

Zomedica's EPS without NRI for the three months ended in Jun. 2026 was $-0.00.

During the past 3 years, the average EPS without NRI Growth Rate was -10.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 12.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Zomedica was 55.30% per year. The lowest was -123.70% per year. And the median was 12.90% per year.

Zomedica  (OTCPK:ZOMDF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Zomedica 3-Year EPS without NRI Growth Rate Related Terms

ZOMDF vs SERA, CVRX, RPID: 3-Year EPS without NRI Growth Rate Comparison

For the Medical Devices subindustry, Zomedica's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zomedica 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Zomedica's 3-Year EPS without NRI Growth Rate falls into.


Zomedica 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

What does a 3-Year EPS without NRI Growth Rate of -10.60% mean?
Zomedica (ZOMDF) has a 3-Year EPS without NRI Growth Rate of -10.60% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Zomedica and its competitors. According to the industry distribution chart, Zomedica ranks #488 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 73.7%.
Is Zomedica's 3-Year EPS without NRI Growth Rate too high?
Zomedica's current 3-Year EPS without NRI Growth Rate is -10.60%. Based on the distribution chart, Zomedica ranks #488 out of 662 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Zomedica's 3-Year EPS without NRI Growth Rate compare to SERA and CVRX?
According to the Medical Devices & Instruments industry distribution chart, Zomedica ranks #488 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places Zomedica in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Zomedica and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zomedica's current 3-Year EPS without NRI Growth Rate is -10.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.08 — trading 56.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -10.60%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Zomedica (ZOMDF), the current 3-Year EPS without NRI Growth Rate is -10.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zomedica Business Description

Address 1101 Technology Drive, Suite 100, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.